LYEL News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, raised $425 million by offering 25 million shares at $17, the midpoint of the range of $16 to $18. At pricing, the company commands a fully diluted market value of $4.7 billion. Lyell states that it is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more

Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, announced terms for its IPO on Wednesday. The South San Francisco, CA-based company plans to raise $425 million by offering 25 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Lyell Immunopharma would command a fully diluted market value of $4.7 billion. ...read more